Fig. 1: Efficacy of CAR-T cell therapy in patients with primary refractory DLBCL. | Nature Communications

Fig. 1: Efficacy of CAR-T cell therapy in patients with primary refractory DLBCL.

From: Cholesterol efflux from C1QB-expressing macrophages is associated with resistance to chimeric antigen receptor T cell therapy in primary refractory diffuse large B cell lymphoma

Fig. 1

a Participant flowchart. b Records of the time of treatment response change in 11 patients who received CAR-T cell therapy. c Treatment response following 1 month (day 29) and 3 months (day 90) of CAR-T cell infusion. d The best percentage of SPD change from baseline. e Progression-free survival and overall survival in patients with objective response (CR/PR, n = 5) and no response (SD/PD, n = 6). Statistical analysis was performed using log-rank tests. CR complete response, PR partial response, SD stable disease, PD progressive disease, SPD sum of perpendicular diameters.

Back to article page